Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sharon Townson Sells 6,000 Shares

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Sharon Townson sold 6,000 shares of the business’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $23.31, for a total value of $139,860.00. Following the completion of the transaction, the insider owned 67,845 shares in the company, valued at $1,581,466.95. This trade represents a 8.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Sharon Townson also recently made the following trade(s):

• On Tuesday, June 23rd, Sharon Townson sold 3,000 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $60,000.00.
• On Wednesday, June 17th, Sharon Townson sold 3,000 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $19.00, for a total transaction of $57,000.00.

Monte Rosa Therapeutics Price Performance

Shares of NASDAQ:GLUE opened at $24.40 on Wednesday. Monte Rosa Therapeutics, Inc. has a fifty-two week low of $4.12 and a fifty-two week high of $25.77. The business has a 50-day moving average of $19.52 and a two-hundred day moving average of $18.98. The stock has a market capitalization of $2.06 billion, a P/E ratio of -16.49 and a beta of 1.56.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). The firm had revenue of $4.21 million during the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. As a group, research analysts expect that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Analyst Ratings Changes

GLUE has been the topic of a number of research reports. Weiss Ratings raised shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Wells Fargo & Company decreased their price target on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Wall Street Zen downgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Guggenheim upped their price objective on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Finally, JPMorgan Chase & Co. increased their target price on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $33.33.

Institutional Trading of Monte Rosa Therapeutics

Several large investors have recently added to or reduced their stakes in the company. State Street Corp raised its position in shares of Monte Rosa Therapeutics by 148.9% during the fourth quarter. State Street Corp now owns 2,107,480 shares of the company’s stock worth $33,045,000 after acquiring an additional 1,260,707 shares during the last quarter. MPM Bioimpact LLC bought a new position in Monte Rosa Therapeutics in the fourth quarter valued at about $18,399,000. AQR Capital Management LLC increased its position in Monte Rosa Therapeutics by 459.4% in the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after purchasing an additional 1,054,406 shares during the period. Braidwell LP acquired a new stake in Monte Rosa Therapeutics in the fourth quarter worth about $14,870,000. Finally, Vestal Point Capital LP bought a new stake in Monte Rosa Therapeutics during the 3rd quarter worth about $5,928,000. 79.96% of the stock is owned by institutional investors.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.